S&P 500   4,561.49 (-0.72%)
DOW   36,161.98 (-0.23%)
QQQ   385.28 (-1.20%)
AAPL   188.83 (-1.26%)
MSFT   368.12 (-1.71%)
META   317.79 (-2.16%)
GOOGL   128.29 (-2.71%)
AMZN   144.38 (-1.80%)
TSLA   236.85 (-0.83%)
NVDA   452.29 (-3.28%)
NIO   7.32 (+2.38%)
BABA   73.07 (-1.24%)
AMD   118.42 (-2.45%)
T   16.58 (-1.07%)
F   10.69 (+1.04%)
MU   74.00 (-2.54%)
CGC   0.73 (+18.59%)
GE   121.54 (-0.78%)
DIS   92.03 (-0.59%)
AMC   7.36 (+7.29%)
PFE   29.36 (+1.56%)
PYPL   59.92 (+0.45%)
XOM   102.50 (-0.48%)
S&P 500   4,561.49 (-0.72%)
DOW   36,161.98 (-0.23%)
QQQ   385.28 (-1.20%)
AAPL   188.83 (-1.26%)
MSFT   368.12 (-1.71%)
META   317.79 (-2.16%)
GOOGL   128.29 (-2.71%)
AMZN   144.38 (-1.80%)
TSLA   236.85 (-0.83%)
NVDA   452.29 (-3.28%)
NIO   7.32 (+2.38%)
BABA   73.07 (-1.24%)
AMD   118.42 (-2.45%)
T   16.58 (-1.07%)
F   10.69 (+1.04%)
MU   74.00 (-2.54%)
CGC   0.73 (+18.59%)
GE   121.54 (-0.78%)
DIS   92.03 (-0.59%)
AMC   7.36 (+7.29%)
PFE   29.36 (+1.56%)
PYPL   59.92 (+0.45%)
XOM   102.50 (-0.48%)
S&P 500   4,561.49 (-0.72%)
DOW   36,161.98 (-0.23%)
QQQ   385.28 (-1.20%)
AAPL   188.83 (-1.26%)
MSFT   368.12 (-1.71%)
META   317.79 (-2.16%)
GOOGL   128.29 (-2.71%)
AMZN   144.38 (-1.80%)
TSLA   236.85 (-0.83%)
NVDA   452.29 (-3.28%)
NIO   7.32 (+2.38%)
BABA   73.07 (-1.24%)
AMD   118.42 (-2.45%)
T   16.58 (-1.07%)
F   10.69 (+1.04%)
MU   74.00 (-2.54%)
CGC   0.73 (+18.59%)
GE   121.54 (-0.78%)
DIS   92.03 (-0.59%)
AMC   7.36 (+7.29%)
PFE   29.36 (+1.56%)
PYPL   59.92 (+0.45%)
XOM   102.50 (-0.48%)
S&P 500   4,561.49 (-0.72%)
DOW   36,161.98 (-0.23%)
QQQ   385.28 (-1.20%)
AAPL   188.83 (-1.26%)
MSFT   368.12 (-1.71%)
META   317.79 (-2.16%)
GOOGL   128.29 (-2.71%)
AMZN   144.38 (-1.80%)
TSLA   236.85 (-0.83%)
NVDA   452.29 (-3.28%)
NIO   7.32 (+2.38%)
BABA   73.07 (-1.24%)
AMD   118.42 (-2.45%)
T   16.58 (-1.07%)
F   10.69 (+1.04%)
MU   74.00 (-2.54%)
CGC   0.73 (+18.59%)
GE   121.54 (-0.78%)
DIS   92.03 (-0.59%)
AMC   7.36 (+7.29%)
PFE   29.36 (+1.56%)
PYPL   59.92 (+0.45%)
XOM   102.50 (-0.48%)

PainReform Stock Price, News & Analysis (NASDAQ:PRFX)

$2.74
+0.21 (+8.30%)
(As of 02:20 PM ET)
Compare
Today's Range
$2.54
▼
$2.80
50-Day Range
$1.85
▼
$3.63
52-Week Range
$1.82
▼
$26.41
Volume
29,301 shs
Average Volume
376,036 shs
Market Capitalization
$2.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media

PRFX stock logo

About PainReform Stock (NASDAQ:PRFX)

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

PRFX Stock Price History

PRFX Stock News Headlines

November 24, 2023 | americanbankingnews.com
PainReform (NASDAQ:PRFX) Trading Up 4.4%
November 19, 2023 | finanznachrichten.de
PainReform Ltd: PainReform Provides Business Update for the Third Quarter of 2023
December 4, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
November 18, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: PainReform (PRFX) and Tenet Healthcare (THC)
November 15, 2023 | finance.yahoo.com
PainReform Provides Business Update for the Third Quarter of 2023
November 12, 2023 | morningstar.com
PainReform Ltd Ordinary Shares PRFX
September 12, 2023 | markets.businessinsider.com
PainReform (PRFX) Gets a Buy from Maxim Group
September 11, 2023 | finance.yahoo.com
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File
December 4, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
September 7, 2023 | finance.yahoo.com
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
September 7, 2023 | finance.yahoo.com
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
September 5, 2023 | finance.yahoo.com
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
August 30, 2023 | finance.yahoo.com
PRFX - PainReform Ltd.
August 11, 2023 | finance.yahoo.com
PainReform Provides Business Update for the Second Quarter of 2023
July 19, 2023 | finanznachrichten.de
PainReform Ltd: PainReform Regains Compliance with Nasdaq Continued Listing Requirements
July 19, 2023 | finance.yahoo.com
PainReform Regains Compliance with Nasdaq Continued Listing Requirements
July 14, 2023 | markets.businessinsider.com
PRFX Stock: The $2.7 Million Reason PainReform Is Up 100% Today
July 14, 2023 | finance.yahoo.com
PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement
July 12, 2023 | marketwatch.com
PainReform Shares Unwind From Tuesday Surge After Pricing
July 12, 2023 | msn.com
PainReform (NASDAQ:PRFX) Tanks on $2.7M Registered Direct Offering
July 12, 2023 | finance.yahoo.com
PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
July 11, 2023 | benzinga.com
What's Going On With PainReform (PRFX) Stock?
July 11, 2023 | benzinga.com
PainReform Shares Halted On Circuit Breaker To The Upside, Stock Now Up 125.4%
July 7, 2023 | msn.com
Why Gorilla Technology Group Are Trading Higher By 52%; Here Are 20 Stocks Moving Premarket
June 15, 2023 | finance.yahoo.com
PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st
June 10, 2023 | markets.businessinsider.com
PainReform (PRFX) Receives a Buy from Maxim Group
June 7, 2023 | benzinga.com
PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
See More Headlines
Receive PRFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PainReform and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
12/04/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRFX
CUSIP
N/A
CIK
1801834
Web
www.painreform.com
Phone
972-3717-7051
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,790,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-77.50%
Return on Assets
-70.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.81
Quick Ratio
8.10

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.92 per share
Price / Book
0.32

Miscellaneous

Outstanding Shares
1,090,000
Free Float
715,000
Market Cap
$2.76 million
Optionable
Not Optionable
Beta
0.50
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Ehud Geller Ph.D.
    Executive Chairman
  • Mr. Ilan Hadar M.B.A. (Age 54)
    CEO & CFO
    Comp: $457k
  • Dr. Sigal Aviel (Age 59)
    Chief Operating Officer
    Comp: $329k
  • Prof. Eli Hazum Ph.D.
    CTO & Director
  • Ms. Rita Keynan (Age 54)
    Vice President of Pharmaceutical Operations
    Comp: $315k
  • Dr. Stephen A. Cooper D.M.D Ph.D.
    Executive Vice President of Development

Key Competitors

View All Competitors














PRFX Stock Analysis - Frequently Asked Questions

How have PRFX shares performed in 2023?

PainReform's stock was trading at $4.1270 on January 1st, 2023. Since then, PRFX stock has decreased by 33.6% and is now trading at $2.74.
View the best growth stocks for 2023 here.

Are investors shorting PainReform?

PainReform saw a decrease in short interest in November. As of November 15th, there was short interest totaling 400 shares, a decrease of 84.0% from the October 31st total of 2,500 shares. Based on an average daily volume of 19,200 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company's shares are sold short.
View PainReform's Short Interest.

When is PainReform's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our PRFX earnings forecast.

How were PainReform's earnings last quarter?

PainReform Ltd. (NASDAQ:PRFX) issued its earnings results on Monday, November, 15th. The company reported ($1.80) EPS for the quarter, topping the consensus estimate of ($4.30) by $2.50.

When did PainReform's stock split?

PainReform's stock reverse split on Monday, July 3rd 2023. The 1-10 reverse split was announced on Monday, July 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of PainReform own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PainReform investors own include Novartis (NVS), AbbVie (ABBV), American Airlines Group (AAL), Bank of America (BAC), Bristol-Myers Squibb (BMY), Clorox (CLX), Cisco Systems (CSCO), CVS Health (CVS), Delta Air Lines (DAL) and DocuSign (DOCU).

When did PainReform IPO?

(PRFX) raised $20 million in an initial public offering on Tuesday, September 1st 2020. The company issued 2,500,000 shares at a price of $8.00 per share. Maxim Group and Joseph Gunnar acted as the underwriters for the IPO.

How do I buy shares of PainReform?

Shares of PRFX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PRFX) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -